The Mother’s Day Classic event engages more than 65,000 participants across over 70 sites each year, with the MDCF team moving to increase their research impact by becoming a dual-cause national event. MDCF participants will be able to take part and fundraise in support of ovarian cancer research, breast cancer research, or both.
Breast cancer continues to be the most diagnosed cancer in women in Australia, while ovarian cancer is the most lethal female cancer, based on survivability.
The new partnership will speed up the progress toward the day that no Australian family suffers the devastation of losing another woman or person to ovarian cancer.
Ovarian Cancer Research Foundation CEO Robin Penty said her group was on a mission to make sure the place where all human life begins – the ovaries – is no longer a place where women’s lives end.
“This exciting new partnership with the Mother’s Day Classic Foundation, will assist fundraising and awareness of ovarian cancer and help all women and girls pay closer attention to their reproductive health as well,” she said.
“On behalf of all those affected by ovarian cancer, and their families, we’re delighted to join this significant and much-admired national event on a very important day for mothers in our calendar.
“We hope you’ll sign up for the Mother’s Day Classic, as we take a giant step forward as an organisation.”
To find out more and sign up for the 27th Mother’s Day Classic on Sunday, May 12: ocrf.com.au.
Mother’s Day Classic to aid ovarian cancer fight
FOR the first time this year, the Mother’s Day Classic Foundation (MDCF) will partner with the Ovarian Cancer Research Foundation (OCRF) to become their second national women’s cancer cause, alongside the National Breast Cancer Foundation (NBCF).
